Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.09.14	New data confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity (NEDA)' based on four key measures of MS (GlobeNewswire)
10.09.14	Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression (GlobeNewswire)
07.09.14	Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide®* (GlobeNewswire)
03.09.14	Gilenya® data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients (GlobeNewswire)
02.09.14	Novartis to unveil new data from three key clinical trials at European Respiratory Society International Congress 2014 (GlobeNewswire)
30.08.14	Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial (GlobeNewswire)
30.08.14	Neues Arzneimittel LCZ696 von Novartis gegen Herzinsuffizienz hat in wegweisender Studie PARADIGM-HF die kardiovaskulär bedingten Todesfälle im Vergleich zum ACE-Inhibitor um 20% gesenkt (GlobeNewswire)
25.08.14	Experten von Novartis und zukünftige wissenschaftliche Führungskräfte befassen sich am internationalen BioCamp 2014 mit dem «Wettlauf mit der Zeit» (GlobeNewswire)
25.08.14	Novartis experts and future scientific leaders meet at International BioCamp 2014 to consider 'The Race Against Time' (GlobeNewswire)
20.08.14	Novartis provides drug candidate compounds to TB Alliance (GlobeNewswire)
11.08.14	Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696 (GlobeNewswire)
11.08.14	Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696 (GlobeNewswire)
30.07.14	KAE609 shows promise as next generation treatment for malaria (GlobeNewswire)
30.07.14	KAE609 ist vielversprechender Kandidat für eine neue Generation von Malariamedikamenten (GlobeNewswire)
29.07.14	Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B (GlobeNewswire)
28.07.14	Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease (GlobeNewswire)
24.07.14	FDA accepts Sandoz application for biosimilar filgrastim (GlobeNewswire)
24.07.14	FDA accepts Sandoz application for biosimilar filgrastim (GlobeNewswire)
17.07.14	Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook (GlobeNewswire)
17.07.14	Novartis setzt im zweiten Quartal die starke Dynamik im Innovationsbereich fort und bekräftigt erneut den Ausblick für das Gesamtjahr (GlobeNewswire)
15.07.14	Novartis to license Google "smart lens" technology (GlobeNewswire)
15.07.14	Novartis announces collaboration with Banner Alzheimer's Institute on a pioneering prevention study for Alzheimer's Disease (GlobeNewswire)
09.07.14	Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of secukinumab (AIN457) in psoriasis patients (GlobeNewswire)
09.07.14	Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting standard, increasing transparency (GlobeNewswire)
09.07.14	Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting standard, increasing transparency (GlobeNewswire)
08.07.14	Novartis reinforces its leadership in research with new global guidelines for Investigator Initiated Trials (IITs) (GlobeNewswire)
07.07.14	Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation (GlobeNewswire)
30.06.14	Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide (GlobeNewswire)
18.06.14	Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day (GlobeNewswire)
17.06.14	Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero® to help protect US adolescents and young adults (GlobeNewswire)
16.06.14	Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines (GlobeNewswire)
10.06.14	Novartis Foundation for Sustainable Development to work with Netherlands Leprosy Relief to help reduce leprosy transmission (GlobeNewswire)
03.06.14	Pivotal Phase III data show polycythemia vera patients on Novartis drug Jakavi® achieved significant improvement in disease control (GlobeNewswire)
02.06.14	Novartis study shows Zykadia(TM) shrank tumors in the majority of patients with ALK+ NSCLC, regardless of prior ALK treatment (GlobeNewswire)
02.06.14	Novartis data at ASCO show LBH589 significantly improved progression-free survival in patients with multiple myeloma (GlobeNewswire)
01.06.14	Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma (GlobeNewswire)
01.06.14	Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology (GlobeNewswire)
28.05.14	World MS Day: Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS (GlobeNewswire)
28.05.14	World MS Day: Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS (GlobeNewswire)
23.05.14	Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure (GlobeNewswire)
23.05.14	Alcon receives positive CHMP opinion for Simbrinza®, a new fixed-dose combination medicine to treat patients with glaucoma (GlobeNewswire)
22.05.14	Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers (GlobeNewswire)
21.05.14	Novartis announces positive results at ATS for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol) (GlobeNewswire)
19.05.14	Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista® (GlobeNewswire)
16.05.14	FDA issues Complete Response Letter for RLX030 for acute heart failure (GlobeNewswire)
15.05.14	Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary (GlobeNewswire)
09.05.14	Novartis data at ARVO 2014 confirm transformational real world outcomes and highlight the safety profile of Lucentis® (GlobeNewswire)
09.05.14	Novartis data at ARVO 2014 confirm transformational real world outcomes and highlight the safety profile of Lucentis® (GlobeNewswire)
05.05.14	Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues (GlobeNewswire)
30.04.14	Novartis announces presentation of data at AAN showing Gilenya® slowed the rate of brain volume loss in MS patients (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Börse New York in Grün: So steht der NASDAQ 100 aktuell
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Börse New York in Grün: So steht der NASDAQ 100 aktuell

20.12.24

Handel in Europa: STOXX 50 schliesst im Minus

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten